Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer

BACKGROUND: BRAF mutation occurs in 5%–10% of metastatic colorectal cancers (mCRCs). Patients with BRAF mutant mCRC exhibit a specific metastatic pattern and poor prognosis. Survival outcomes are heterogeneous in cases of mCRC with a BRAF mutation. The optimal first‐line therapy is still controversi...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ting, Li, Jian, Wang, Zhenghang, Zhang, Xiaotian, Zhou, Jun, Lu, Zhihao, Shen, Lin, Wang, Xicheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225206/
https://www.ncbi.nlm.nih.gov/pubmed/36912150
http://dx.doi.org/10.1002/cam4.5783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225206/
https://www.ncbi.nlm.nih.gov/pubmed/36912150
http://dx.doi.org/10.1002/cam4.5783

Ejemplares similares